Pulmonary Arterial Hypertension (PAH) is a heterogenic group of devastating disorders that characterizes higher rates of mortality and morbidity worldwide. Recent clinical studies have shown that clinical features, hemodynamic parameters, echocardiography patter, multi-spiral computer tomography findings, exercise capacity, and anti-nuclear antibody profiles could be used as predictors of clinical severity and outcomes in PAH patients. However, the reliability, sensitivity, specificity and predictive value are derived from PAH patients with different comorbidities and specific complications associated with CTD,  congenital heart disease and respiratory disease might be unacceptable. The aim of the review: to summarize the knowledge regarding predictive value of several biomarkers in PAH individuals. The review is argued the perspective to utilize single sample and serial measurements of biomarkers as a regulatory peptide contributed in PAH pathogenesis aimed to improve prediction of PAH development and progression.